These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3492026)

  • 1. Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course.
    Swaak AJ; van Rooyen A; Vogelaar C; Pillay M; Hack E
    Rheumatol Int; 1986; 6(5):221-6. PubMed ID: 3492026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
    Charlesworth JA; Peake PW; Golding J; Mackie JD; Pussell BA; Timmermans V; Wakefield D
    Ann Rheum Dis; 1989 Feb; 48(2):153-9. PubMed ID: 2784659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. A prospective study.
    Swaak AJ; Groenwold J; Hannema A; Hack CE
    Rheumatol Int; 1985; 5(5):215-20. PubMed ID: 3877968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
    Röther E; Lang B; Coldewey R; Hartung K; Peter HH
    Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.
    Swaak AJ; Hannema A; Vogelaar C; Boom FA; van Es L; van Aalst R; Statius van Eps LW
    Rheumatol Int; 1982; 2(4):161-6. PubMed ID: 6984977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.
    Nguyen CP; Cao VV; Fehér J; Gergely P
    Acta Med Hung; 1988; 45(2):145-59. PubMed ID: 3266790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus.
    Tsukamoto H; Ueda A; Nagasawa K; Tada Y; Niho Y
    Clin Exp Immunol; 1990 Nov; 82(2):257-61. PubMed ID: 2242606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.
    Swaak AJ; Groenwold J; Bronsveld W
    Ann Rheum Dis; 1986 May; 45(5):359-66. PubMed ID: 3487292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.
    Davis P; Cumming RH; Verrier-Jones J
    Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course.
    Swaak AJ; Han H; van Rooyen A; Pillay M; Hack CE
    Rheumatol Int; 1988; 8(2):61-5. PubMed ID: 3261029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus.
    Weinstein A; Bordwell B; Stone B; Tibbetts C; Rothfield NF
    Am J Med; 1983 Feb; 74(2):206-16. PubMed ID: 6600582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A; Barr SG; Magder LS; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vivo metabolism of the third component of complement in systemic lupus erythematosus.
    Petz LD; Powers R; Fries JR; Cooper NR; Holman HR
    Arthritis Rheum; 1977; 20(7):1304-13. PubMed ID: 303101
    [No Abstract]   [Full Text] [Related]  

  • 15. The significance of serial measurement of serum anti-native DNA antibodies and complement C3 and C4 components in the management of patients with systemic lupus erythematosus.
    Grennan DM; Moseley A; Sloane D; Pumphrey R; Dick WC; Buchanan WW
    Aust N Z J Med; 1977 Dec; 7(6):625-9. PubMed ID: 306817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serological and immunohistochemical studies in pregnant women with systemic lupus erythematosus].
    Sakui H; Yoshimura Y; Tada S; Tateyama Y; Shiraki M; Kokubo M; Torikai K; Kawakami S; Fukushima M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Mar; 41(3):249-56. PubMed ID: 2786540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus.
    Garabet L; Gilboe IM; Mowinckel MC; Jacobsen AF; Mollnes TE; Sandset PM; Jacobsen EM
    Scand J Immunol; 2016 Aug; 84(2):95-9. PubMed ID: 27135178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL; Jones AC; Brown NS; Powell RJ
    Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features.
    Gladman DD; Urowitz MB; Keystone EC
    Am J Med; 1979 Feb; 66(2):210-5. PubMed ID: 218447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.